

CURRICULUM VITAE**Name:** **Professor Israel Moshe Barbash, M.D.****ID:** **025671116****Email:** ibarbash@gmail.com**Tel :** +972-52-666-9132**FACULTY/DEPT** Associate Professor of Cardiology

Sackler Faculty of Medicine, Tel Aviv University

HOSPITAL/DEPT: Director of catheterization laboratory services

Interventional Cardiology Unit

The Olga and Lev Leviev Heart Center

Chaim Sheba Medical Center

HOME ADDRESS 31 TOPAZ STREET, SHOHAM**DATE AND PLACE OF BIRTH** AUGUST 11, 1973 ISRAEL**ZAHAL (ISRAELI) MILITARY****SERVICE** AIR FORCE, NOVEMBER 1991 – NOVEMBER 1994**MARITAL STATUS** MARRIED + 3

A. Education

November 1994 - November 2002	Bachelor Degree in Medical Sciences Ben-Gurion University of The Negev, Beer-Sheva, Israel
	Medical School Ben-Gurion University of The Negev, Beer-Sheva, Israel
Title of Doctoral Dissertation:	Management and outcome of cardiogenic shock complicating acute myocardial infarction in hospitals with and without on-site catheterization facilities
Supervised by:	Jonathan Leor, MD
Date Awarded:	December 12, 2002

B. Further Studies

November 2000 - October 31 2001	Research Fellowship Neufeld Cardiac Research Institute Tel Aviv University, Tel-Aviv, Israel
November 1, 2001 - October 31, 2002	Internship - Clinical Sheba Medical Center, Tel Aviv University, Israel
February 1, 2003 - January 31, 2009	Internal Medicine Residency and Cardiovascular Disease Fellowship as part of combined Internal Medicine/Cardiology 6-year program Sheba Medical Center, Tel Aviv University, Israel
January 1, 2009 – June 30, 2011	Visiting Research Fellow, Cardiovascular Intervention Program, Translational Medicine Branch, National Heart Lung and Blood Institute, National Institute of Health
July 2009	Level 2 Cardiac CT training Johns Hopkins University, Baltimore, MD
July 2011 – June 2013	Interventional Cardiology Fellowship MedStar - Cleveland Clinic Washington Hospital Center, Georgetown University, Washington DC

ACCREDITATION**Israel**

Bachelor Degree in Medical Sciences	June 15, 1998
Medical Doctor 2002	December 12,
Board Certified in Internal Medicine, <i>Summa Cum Laude</i> (Israel Medical Association)	March 26, 2008
Board Certified in Cardiovascular Disease (Israel Medical Association)	February 3, 2009

United States

United States Medical Licensing Examination (USMLE) Step 2 Exam– Clinical Knowledge 2001	February 28,
United States Medical Licensing Examination (USMLE) Step 1 Exam	March 28, 2001
United States Medical Licensing Examination (USMLE) Step 2 Exam – Clinical Skills	August 3, 2007
Educational Commission for Foreign Medical Graduates (ECFMG) certification	October 12, 2007
United States Medical Licensing Examination (USMLE) Step 3 Exam	April 7, 2008

C. ACADEMIC & PROFESSIONAL ACTIVITIES & ACHIEVEMENTS**C1. ACADEMIC EXPERIENCE**

May 2009	15 th Annual Interventional Cardiology Fellows Course, Cardiovascular Research Foundation, Miami, FL
October 2009 – December 2009	Biomedical Applications of Magnetic Resonance Imaging Foundation For Advanced Education in the Sciences Inc. Bethesda, MD

C2. PROFESSIONAL EXPERIENCE**PATENTS**

2008	Methods of isolating cardiac stem cells, banking and uses thereof. Ramot Tel-Aviv University LTD, Tel-Hashomer Medical Research Infrastructure and Services LTD, Itzhaki-Alfia A, Barbash IM, Leor J. PCT/IL2008/000026.
2010	Closure device for cardiac surgery. Lore R, Ofir Y, Lederman RJ, Barbash IM. 61/382,931.

C3. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS

<i>Date</i>	<i>Country</i>	<i>Subject / Meeting</i>	<i>Role</i> (Speaker, Member of Steering Committee, Active Participation etc.)
June 2000	Jerusalem, Israel	Intensive Cardiac Care 2 nd International meeting	Invited lecture
August 2004	Munich, Germany	European Society of Cardiology Congress	Abstract presentation
September 2005	Tel-Aviv, Israel	4 th International Meeting, Intensive Cardiac Care	Invited lecture
October 2006	Eilat, Israel	The 11 th Annual Meeting of The Israeli Society for Research, Prevention and Treatment of Atherosclerosis in Conjunction with The Frontiers in Cardiovascular Science	Invited lecture
October 2007	Tel-Aviv, Israel	5 th International Meeting, Intensive Cardiac Care	Invited lecture
December 2007	Tel-Aviv, Israel	Innovations in Cardiovascular Interventions	Invited lecture
February 2009	Washington DC	Cardiovascular Research Technologies 2009	Participation

Name: Israel M BarbashDegree: MDCV Updated: October 21, 2018

October 2009	Washington DC	Transcatheter Cardiovascular Therapeutics 2009	Participation
January 2010	Phoenix, AZ	Annual meeting of The Society for Cardiovascular Magnetic Resonance	Participation
February 2010	Washington DC	Cardiovascular Research Technologies 2010	Participation
February 2011	Washington DC	Cardiovascular Research Technologies 2011	Abstract presentation
February 2012	Washington DC	Cardiovascular Research Technologies 2012	Abstract presentation
March 2012	Chicago, IL	2012 Annual Scientific Session and ACC-i2 with TCT	Abstract presentation
October 2012	Miami, FL	Transcatheter Cardiovascular Therapeutics 2012	Abstract presentation
November 2012	Los Angeles, CA	American Heart Association Scientific Sessions	Abstract presentation
February 2013	Washington DC	Cardiovascular Research Technologies 2013	Faculty
May 2014	Paris, France	EuroPCR meeting	Abstract presentation
December 2014	Tel Aviv, Israel	Innovations in Cardiovascular Interventions	Participation
February 2015	Washington, DC	Cardiovascular Research Technologies 2015	Faculty
April 2015	Tel-Aviv, Israel	Israel Heart Society annual meeting	Participation
May 2015	Paris, France	EuroPCR meeting	Abstract presentation
December 2015	Tel Aviv, Israel	Innovations in Cardiovascular Interventions	Participation
February 2016	Washington, DC	Cardiovascular Research Technologies 2016	Faculty
April 2016	Tel-Aviv, Israel	Israel Heart Society annual meeting	Abstract presentation
December 2016	Tel Aviv, Israel	Innovations in Cardiovascular Interventions	Invited lecture
February 2017	Washington, DC	Cardiovascular Research Technologies 2017	Faculty
April 2017	Tel-Aviv, Israel	Israel Heart Society annual meeting	Participation
May 2017	Paris, France	EuroPCR meeting	Abstract presentation
August 2017	Barcelona, Spain	ESC Congress	Faculty
November 2017	Frankfurt, Germany	LAA CSI Focus	Participation

Name: Israel M Barbash

Degree: MD

CV Updated: October 21, 2018

December 2017	Tel Aviv, Israel	Innovations in Cardiovascular Interventions	Participation
March 2018	Washington, DC	Cardiovascular Research Technologies 2018	Faculty
March 2018	Orlando, FL	ACC Scientific Sessions 2018	Faculty
June 2018	Tel Aviv	11th International Conference Acute Cardiac Care	Faculty

C4. MEMBERSHIP IN PROFESSIONAL SOCIETIES

Years (period)	Name of Organization
1998-present	Israel Society of Cardiology
2003-present	European Society of Cardiology
2007-2008	American Heart Association, Basic Science Council
2011-2013	American College of Cardiology

D. DOCTORAL STUDENTS MENTORED BY CANDIDATE

	Name	Thesis
1.	Michael Michlin	Evaluation of discrepancies on the echocardiographic and invasive hemodynamic evaluation of severity of aortic valve stenosis
2.	Yasmin Sharif	Anticoagulation after transcatheter aortic valve replacement
3.	Ariel Banai	Left atrial appendage occlusion for patients with end stage renal disease

E. M.A./M.Sc. STUDENTS

N/A

F. GRANTS

PEER-REVIEWED RESEARCH GRANTS

Years	Investigator	Granted by (Principal / Institute/Company other)	Subject	Total Amount	Comments
2001	PI: Barbash IM.	Itzhak Tiber Fund Research Grant, Tel-Aviv University.	Interventional MRI for Monitoring Changes in Morphology of Rat Heart Following Myocardial Infarction and Assessing Guided Percutaneous Gene Therapy.	\$3,000	
2001	PI: Barbash IM.	Itzhak Tiber Fund Research Grant, Tel-Aviv University.	Stem cell base therapy for myocardial regeneration.	\$3,000	
2003	PI: Barbash IM.	Nicholas and Elizabeth Slezak Super Center for Cardiac Research and Biomedical Engineering Research Grant, Tel Aviv University.	Stem cell base therapy for myocardial regeneration.	\$5,000	
2004	PI: Barbash IM.	The Israel Academy of Sciences and Humanities. The B. de Rothschild Fund for the Advancement of Science in Israel.		\$70,000	<i>A unique 3-year national Clinician-Investigator program to support young physicians in performing advanced bench to bedside research. 3-4 candidates are elected annually.</i>
2004		Israel Heart Society grant for participation in the European Society of Cardiology annual meeting.		\$1,500	
2008	Co- PI: Barbash IM.	European Commission, 7 th Framework Programme for Research and Technological Development.	<i>Therapy after myocardial infarction: Repair by stem and progenitor cell mobilization and transfer: Infarct Cell Therapy [HEALTH-F2-2009-222995].</i>	€280,000	<i>European-based collaborative of small-scale focused research project (Total funding for 9 CoPIs X~280K = €2,700,000 for 3 years). The general objective of the project is to promote tissue repair after heart infarct and chronic ischemic heart disease. It</i>

includes the identification and modification of key regulatory proteins of stem cell release, recruitment and activation, different adult and embryonic stem cell line preparations and the use of scaffolds to improve cell transfer and to achieve tissue engineering in vitro.

2014	PI: Barbash IM	Seymour Fefer Cardiovascular Research Grant	<i>Nanoparticle-based theranostics to detect and treat atherosclerosis in coronary arteries</i>	200,000 NIS
2014	PI: Barbash IM	Seymour Fefer Cardiovascular Research Grant	<i>Prediction of clinical outcome and left ventricular functional recovery after transcatheter aortic valve implantation in patients with impaired left ventricular function: Cardiac magnetic resonance imaging study</i>	40,000 NIS

G. AWARDS

ACADEMIC AWARDS

- 2001 Klapholtz Award for Cardiovascular Research, Tel Aviv University. Stem cell base therapy for myocardial regeneration.
- 2004 Neufeld prize. Israel Heart Society. Annual Meeting.
- 2006 The Talpiot Medical Leadership Program at the Sheba Medical Center. (\$2000)
- 2007 American Heart Association, Council on Basic Cardiovascular Sciences, New Investigator Travel Award. (\$500)

H. Member of Editorial Board/ Reviewer (International Journals)

Name: Israel M Barbash

Degree: MD

CV Updated: October 21, 2018

SCIENTIFIC JOURNAL REVIEWS

<i>Period</i>	<i>Journal</i>
2009-present	American Journal of Cardiology
2009-2011	Cardiovascular Research
2009-present	European Heart Journal
2009	Heart Journal
2011-present	Cardiovascular Revascularization Medicine
2014-present	Catheterization and Cardiovascular Interventions
2014-present	EuroIntervention
2016-present	European Heart of Heart Failure
2016-present	PLOS One
2016-present	Harefuah
2017-present	Expert Review of Cardiovascular Therapy
2018-present	The Israel Medical Association Journal (IMAJ)

MEMBER OF EDITORIAL BOARD

2018-present	Cardiovascular Revascularization Medicine
--------------	---

SCIENTIFIC PUBLICATIONS**B.1. ORIGINAL ARTICLES****B.1. Articles Published**

- B1-1** **Barbash IM**, Halperin P, Rot A, Hod H, Barbash GI.
Comparison of Baseline Characteristics and Outcome of Patients with Chest Pain Brought to the Hospital by Private Versus Public Mobile Intensive Care Units.
J Thromb Thrombolysis. 1998 Nov;6(3):207-209. PubMed PMID: 10751803.
Impact Factor of 1.985 (HEMATOLOGY 44/67, Q3 and PERIPHERAL VASCULAR DISEASE 39/68, Q3).
Times Cited: 0
- B1-2** **Barbash IM**, Ilia R, Gilutz H, Boyko V, Battler A, Leor J.
Cardiogenic shock: single center experience with and without on-site catheterization facilities.
Cardiology. 2000;93(1-2):87-92. PubMed PMID: 10894912.
Impact Factor of 1.519 (CARDIAC & CARDIOVASCULAR SYSTEMS 71/124, Q3)
Times Cited: 1
- B1-3** Leor J, Aboulafia-Etzion S, Dar A, Shapiro L, **Barbash IM**, Battler A, Granot Y, Cohen S.
Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium?
Circulation. 2000 Nov 7;102(19 Suppl 3):III56-61. PubMed PMID: 11082363.
Impact Factor of 15.202 (CARDIAC & CARDIOVASCULAR SYSTEMS 1/124, Q1 or PERIPHERAL VASCULAR DISEASE 1/68, Q1)
Times Cited: 275
- B1-4** **Barbash IM**, Hasdai D, Behar S, Boyko V, Gottlieb S, Ilia R, Battler A, Leor J; Israeli Thrombolytic Survey Group.
Usefulness of pre- versus postadmission cardiogenic shock during acute myocardial infarction in predicting survival.
Am J Cardiol. 2001 May 15;87(10):1200-3; A7. PubMed PMID: 11356399.
Impact Factor of 3.209 in (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 4
- B1-5** Etzion S, Battler A, **Barbash IM**, Cagnano E, Zarin P, Granot Y, Kedes LH, Kloner RA, Leor J.
Influence of embryonic cardiomyocyte transplantation on the progression of heart failure in a rat model of extensive myocardial infarction.
J Mol Cell Cardiol. 2001 Jul;33(7):1321-30. PubMed PMID: 11437538.
Impact Factor of 5.148. (CARDIAC & CARDIOVASCULAR SYSTEMS 18/124, Q1 or CELL BIOLOGY 45/185, Q1)
Times Cited: 135
- B1-6** **Barbash IM**, Behar S, Battler A, Hasdai D, Boyko V, Gottlieb S, Leor J.
Management and outcome of cardiogenic shock complicating acute myocardial infarction in hospitals with and without on-site catheterisation facilities.
Heart. 2001 Aug;86(2):145-9. PubMed PMID: 11454827.
Impact Factor of 5.014 (CARDIAC & CARDIOVASCULAR SYSTEMS 22/124, Q1)
Times Cited: 9

- B1-7** **Barbash IM**, Freimark D, Gottlieb S, Hod H, Hasin Y, Battler A, Crystal E, Matetzky S, Boyko V, Mandelzweig L, Behar S, Leor J; Israeli working group on intensive cardiac care, Israel heart society. Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre-hospital administration. *Cardiology*. 2002;98(3):141-7. PubMed PMID: 12417813.
Impact Factor of 1.519 (CARDIAC & CARDIOVASCULAR SYSTEMS 71/124, Q3)
Times Cited: 27
- B1-8** **Barbash IM**, Battler A, Behar S, Boyko V, Gottlieb S, Hasdai D, Leor J; Israeli Thrombolytic Survey Group. Aspirin and percutaneous coronary angioplasty are associated with a decline in mortality from cardiogenic shock. Results from a national Israeli survey, 1992--1998. *Cardiology*. 2001;95(3):119-25. PubMed PMID: 11474156.
Impact Factor of 1.519 (CARDIAC & CARDIOVASCULAR SYSTEMS 71/124, Q3)
Times Cited: 3
- B1-9** Freimark D, Matetzky S, Leor J, Boyko V, **Barbash IM**, Behar S, Hod H. Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. *Am J Cardiol*. 2002 Feb 15;89(4):381-5. PubMed PMID: 11835915.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 27
- B1-10** Etzion S, **Barbash IM**, Feinberg MS, Zarin P, Miller L, Guetta E, Holbova R, Kloner RA, Kedes LH, Leor J. Cellular cardiomyoplasty of cardiac fibroblasts by adenoviral delivery of MyoD ex vivo: an unlimited source of cells for myocardial repair. *Circulation*. 2002 Sep 24;106(12 Suppl 1):I125-30. PubMed PMID: 12354721.
Impact Factor of 15.202 (CARDIAC & CARDIOVASCULAR SYSTEMS 1/124, Q1)
Times Cited: 3
- B1-11** **Barbash IM**, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. *Circulation*. 2003 Aug 19;108(7):863-8. PubMed PMID: 12900340.
Impact Factor of 15.202 (CARDIAC & CARDIOVASCULAR SYSTEMS 1/124, Q1)
Times Cited: 463
- B1-12** **Barbash IM**, Leor J, Feinberg MS, Tessone A, Aboulafia-Etzion S, Orenstein A, Ruiz-Cabello J, Cohen JS, Mardor Y. Interventional magnetic resonance imaging for guiding gene and cell transfer in the heart. *Heart*. 2004 Jan;90(1):87-91. PubMed PMID: 14676253.
Impact Factor of 5.014 (CARDIAC & CARDIOVASCULAR SYSTEMS 22/124, Q1)
Times Cited: 16
- B1-13** Leor J, Guetta E, Feinberg MS, Galski H, Bar I, Holbova R, Miller L, Zarin P, Castel D, **Barbash IM**, Nagler A. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. *Stem Cells*. 2006 Mar;24(3):772-80. Erratum in: Stem Cells. 2006 Jun;24(6):1627. PubMed PMID: 16195418.

Impact Factor of 7.701 (BIOTECHNOLOGY & APPLIED MICROBIOLOGY 8/160, Q1 or CELL & TISSUE ENGINEERING 2/17, Q1 or CELL BIOLOGY 27/185, Q1 or HEMATOLOGY 4/67, Q1 or ONCOLOGY 14/197, Q1)
Times Cited: 66

- B1-14** Tessone A, Feinberg MS, **Barbash IM**, Reich R, Holbova R, Richmann M, Mardor Y, Leor J. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. **Cardiovasc Drugs Ther.** 2005 Dec;19(6):383-90. PubMed PMID: 16435072.
Impact Factor of 2.673 (CARDIAC & CARDIOVASCULAR SYSTEMS 48/124, Q2 or PHARMACOLOGY & PHARMACY 99/261, Q2)
Times Cited: 15
- B1-15** Leor J, Rozen L, Zuloff-Shani A, Feinberg MS, Amsalem Y, **Barbash IM**, Kachel E, Holbova R, Mardor Y, Daniels D, Ocherashvili A, Orenstein A, Danon D. Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. **Circulation.** 2006 Jul 4;114(1 Suppl):I94-100. PubMed PMID: 16820652.
Impact Factor of 15.202 (CARDIAC & CARDIOVASCULAR SYSTEMS 1/124, Q1)
Times Cited: 27
- B1-16** Tessone A, Gottlieb S, **Barbash IM**, Garty M, Porath A, Tenenbaum A, Hod H, Boyko V, Mandelzweig L, Behar S, Leor J. Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency. **Cardiology.** 2007;108(3):193-9. PubMed PMID: 17095865.
Impact Factor of 1.519 (CARDIAC & CARDIOVASCULAR SYSTEMS 71/124, Q3)
Times Cited: 14
- B1-17** Amsalem Y, Mardor Y, Feinberg MS, Landa N, Miller L, Daniels D, Ocherashvili A, Holbova R, Yosef O, **Barbash IM**, Leor J. Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. **Circulation.** 2007 Sep 11;116(11 Suppl):I38-45. PubMed PMID: 17846324.
Impact Factor of 15.202 (CARDIAC & CARDIOVASCULAR SYSTEMS 1/124, Q1)
Times Cited: 45
- B1-18** Barsheshet A, Hod H, Shechter M, Sharabani-Yosef O, Rosenthal E, **Barbash IM**, Matetzky S, Tal R, Bentancur AG, Sela BA, Nagler A, Leor J. The effects of external counter pulsation therapy on circulating endothelial progenitor cells in patients with angina pectoris. **Cardiology.** 2008;110(3):160-6. PubMed PMID: 18057883.
Impact Factor of 1.519 (CARDIAC & CARDIOVASCULAR SYSTEMS 71/124, Q3)
Times Cited: 9
- B1-19** Itzhaki-Alfia A, Leor J, Raanani E, Sternik L, Spiegelstein D, Netser S, Holbova R, Pevsner-Fischer M, Lavee J, **Barbash IM**. Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells. **Circulation.** 2009 Dec 22;120(25):2559-66. PubMed PMID: 19996019.
Impact Factor of 15.202 (CARDIAC & CARDIOVASCULAR SYSTEMS 1/124, Q1)
Times Cited: 43

- B1-20** **Barbash IM**, Saikus CE, Ratnayaka K, Faranesh AZ, Kocaturk O, Wu V, Bell JA, Schenke WH, Raman VK, Lederman RJ.
Limitations of closing percutaneous transthoracic ventricular access ports using a commercial collagen vascular closure device.
Catheter Cardiovasc Interv. 2011 Jun 1;77(7):1079-85. PubMed PMID: 21234923.
Impact Factor of 2.514 (CARDIAC & CARDIOVASCULAR SYSTEMS 55/124, Q2)
Times Cited: 3
- B1-21** Wu V, **Barbash IM**, Ratnayaka K, Saikus CE, Sonmez M, Kocaturk O, Lederman RJ, Faranesh AZ.
Adaptive noise cancellation to suppress electrocardiography artifacts during real-time interventional MRI.
J Magn Reson Imaging. 2011 May;33(5):1184-93. PubMed PMID: 21509878.
Impact Factor of 2.566 (RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 38/120, Q2)
Times Cited: 4
- B1-22** Ben-Dor I, Gaglia MA Jr, **Barbash IM**, Maluenda G, Hauville C, Gonzalez MA, Sardi G, Laynez-Carnicero A, Torguson R, Okubagzi P, Xue Z, Goldstein SA, Suddath WO, Kent KM, Lindsay J, Satler LF, Pichard AD, Waksman R.
Comparison between Society of Thoracic Surgeons score and logistic EuroSCORE for predicting mortality in patients referred for transcatheter aortic valve implantation.
Cardiovasc Revasc Med. 2011 Nov-Dec;12(6):345-9. PubMed PMID: 21741324.
(No Impact Factor)
Times Cited: 35
- B1-23** **Barbash IM**, Schenke WH, Halabi M, Ratnayaka K, Faranesh AZ, Kocaturk O, Lederman RJ.
Experimental model of large pulmonary embolism employing controlled release of subacute caval thrombus in swine.
J Vasc Interv Radiol. 2011 Oct;22(10):1471-7. PubMed PMID: 21802315.
Impact Factor of 2.002 (RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 48/120, Q2)
Times Cited: 0
- B1-24** Maluenda G, Ben-Dor I, Laynez-Carnicero A, **Barbash IM**, Sardi G, Gaglia MA Jr, Mitulescu L, Torguson R, Goldstein SA, Wang Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R.
Changes in mitral regurgitation after balloon aortic valvuloplasty.
Am J Cardiol. 2011 Dec 15;108(12):1777-82. PubMed PMID: 21924392.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 2
- B1-25** Saikus CE, Ratnayaka K, **Barbash IM**, Colyer JH, Kocaturk O, Faranesh AZ, Lederman RJ.
MRI-guided vascular access with an active visualization needle.
J Magn Reson Imaging. 2011 Nov;34(5):1159-66. PubMed PMID: 22006552.
Impact Factor of 2.566 (RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 38/120, Q2)
Times Cited: 4
- B1-26** Maluenda G, Ben-Dor I, **Barbash IM**, Corso PJ, Boyce SW, Satler LF, Pichard AD, Waksman R.
Fluoroscopy use and left anterior descending artery angiography to guide transapical access in patients with prior cardiac surgery.
Cardiovasc Revasc Med. 2012 Mar-Apr;13(2):106-10. PubMed PMID: 22177612.
(No Impact Factor)
Times Cited: 0

- B1-27** **Barbash IM**, Saikus CE, Faranesh AZ, Ratnayaka K, Kocaturk O, Chen MY, Bell JA, Virmani R, Schenke WH, Hansen MS, Slack MC, Lederman RJ.
Direct percutaneous left ventricular access and port closure: pre-clinical feasibility.
JACC Cardiovasc Interv. 2011 Dec;4(12):1318-25. PubMed PMID: 22192372.
Impact Factor of 6.552 (CARDIAC & CARDIOVASCULAR SYSTEMS 8/124, Q1)
Times Cited: 6
- B1-28** Ratnayaka K, Saikus CE, Faranesh AZ, Bell JA, **Barbash IM**, Kocaturk O, Reyes CA, Sonmez M, Schenke WH, Wright VJ, Hansen MS, Slack MC, Lederman RJ.
Closed-chest transthoracic magnetic resonance imaging-guided ventricular septal defect closure in swine.
JACC Cardiovasc Interv. 2011 Dec;4(12):1326-34. PubMed PMID: 22192373.
Impact Factor of 6.552 (CARDIAC & CARDIOVASCULAR SYSTEMS 8/124, Q1)
Times Cited: 7
- B1-29** Waksman R, **Barbash IM**, Dvir D, Torguson R, Ben-Dor I, Maluenda G, Xue Z, Satler LF, Suddath WO, Kent KM, Pichard AD.
Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.
Am J Cardiol. 2012 May 1;109(9):1288-94. PubMed PMID: 22341925.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 7
- B1-30** **Barbash IM**, Ben-Dor I, Torguson R, Maluenda G, Xue Z, Gaglia MA Jr, Sardi G, Satler LF, Pichard AD, Waksman R.
Clinical predictors for failure of percutaneous coronary intervention in ST-elevation myocardial infarction.
J Interv Cardiol. 2012 Apr;25(2):111-7. PubMed PMID: 22372924.
Impact Factor of 1.500 (CARDIAC & CARDIOVASCULAR SYSTEMS 73,124, Q3)
Times Cited: 1
- B1-31** Laynez A, Sardi G, Hauville C, **Barbash IM**, Pakala R, Torguson R, Xue Z, Satler LF, Pichard AD, Waksman R.
Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
Catheter Cardiovasc Interv. 2013 Apr;81(5):759-65. PubMed PMID: 22488756.
Impact Factor of 2.514 (CARDIAC & CARDIOVASCULAR SYSTEMS 55/124, Q2)
Times Cited: 3
- B1-32** **Barbash IM**, Cecchini S, Faranesh AZ, Virag T, Li L, Yang Y, Hoyt RF, Kornegay JN, Bogan JR, Garcia L, Lederman RJ, Kotin RM.
MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy.
Gene Ther. 2013 Mar;20(3):274-82. PubMed PMID: 22551778.
Impact Factor of 4.321 (BIOCHEMISTRY & MOLECULAR BIOLOGY 70/290, Q1 or BIOTECHNOLOGY & APPLIED MICROBIOLOGY 22/160, Q1 or GENETICS & HEREDITY 33/161, Q1 or MEDICINE, RESEARCH & EXPERIMENTAL 25/121, Q1)
Times Cited: 1
- B1-33** Bell JA, Saikus CE, Ratnayaka K, **Barbash IM**, Faranesh AZ, Franson DN, Sonmez M, Slack MC, Lederman RJ, Kocaturk O.

- Active delivery cable tuned to device deployment state: enhanced visibility of nitinol occluders during preclinical interventional MRI.
J Magn Reson Imaging. 2012 Oct;36(4):972-8. PubMed PMID: 22707441.
Impact Factor of 2.566 (RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 38/120, Q2)
Times Cited: 1
- B1-34** **Barbash IM**, Ben-Dor I, Dvir D, Maluenda G, Xue Z, Torguson R, Satler LF, Pichard AD, Waksman R. Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement.
Am Heart J. 2012 Jun;163(6):1031-6. PubMed PMID: 22709757.
Impact Factor of 4.497 (CARDIAC & CARDIOVASCULAR SYSTEMS 23/124, Q1)
Times Cited: 11
- B1-35** Ben-Dor I, Dvir D, **Barbash IM**, Okubagzi P, Torguson R, Xue Z, Lindsay J, Satler LF, Pichard AD, Waksman R. Outcomes of patients with severe aortic stenosis at high surgical risk evaluated in a trial of transcatheter aortic valve implantation.
Am J Cardiol. 2012 Oct 1;110(7):1008-14. PubMed PMID: 22721576.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 2
- B1-36** Laynez A, Ben-Dor I, **Barbash IM**, Hauville C, Sardi G, Maluenda G, Xue Z, Satler LF, Pichard AD, Lindsay J, Waksman R. Frequency of conduction disturbances after Edwards SAPIEN percutaneous valve implantation.
Am J Cardiol. 2012 Oct 15;110(8):1164-8. PubMed PMID: 22770935.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 2
- B1-37** Ben-Dor I, Looser PM, Maluenda G, Weddington TC, Kambouris NG, **Barbash IM**, Hauville C, Okubagzi P, Corso PJ, Satler LF, Pichard AD, Waksman R. Transcatheter aortic valve replacement under monitored anesthesia care versus general anesthesia with intubation.
Cardiovasc Revasc Med. 2012 Jul-Aug;13(4):207-10. PubMed PMID: 22818531.
(No Impact Factor)
Times Cited: 2
- B1-38** Ratnayaka K, Faranesh AZ, Hansen MS, Stine AM, Halabi M, **Barbash IM**, Schenke WH, Wright VJ, Grant LP, Kellman P, Kocaturk O, Lederman RJ. Real-time MRI-guided right heart catheterization in adults using passive catheters.
Eur Heart J. 2013 Feb;34(5):380-9. PubMed PMID: 22855740.
Impact Factor of 14.097 (CARDIAC & CARDIOVASCULAR SYSTEMS 2/124, Q1)
Times Cited: 5
- B1-39** Ben-Dor I, Maluenda G, Dvir D, **Barbash IM**, Okubagzi P, Torguson R, Lindsay J, Satler LF, Pichard AD, Waksman R. Balloon aortic valvuloplasty for severe aortic stenosis as a bridge to transcatheter/surgical aortic valve replacement.
Catheter Cardiovasc Interv. 2013 Oct 1;82(4):632-7. PubMed PMID: 23015369.
Impact Factor of 2.514 (CARDIAC & CARDIOVASCULAR SYSTEMS 55/124, Q2)
Times Cited: 1
- B1-40** Badr S, **Barbash IM**, Dvir D, Torguson R, Xue Z, Kitabata H, Sardi G, Loh JP, Pichard AD, Waksman R. Safety and efficacy of everolimus-eluting stents versus sirolimus-eluting stents in women.

Am J Cardiol. 2013 Jan 1;111(1):21-5. PubMed PMID: 23040594.

Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)

Times Cited: 0

B1-41 **Barbash IM**, Dvir D, Ben-Dor I, Corso PJ, Goldstein SA, Wang Z, Bond E, Okubagzi PG, Satler LF, Pichard AD, Waksman R.

Impact of transapical aortic valve replacement on apical wall motion.

J Am Soc Echocardiogr. 2013 Mar;26(3):255-60. PubMed PMID: 23298943.

Impact Factor of 4.277 (CARDIAC & CARDIOVASCULAR SYSTEMS 26/124, Q1)

Times Cited: 1

B1-42 Halabi M, Ratnayaka K, Faranesh AZ, Hansen MS, **Barbash IM**, Eckhaus MA, Wilson JR, Chen MY, Slack MC, Kocaturk O, Schenke WH, Wright VJ, Lederman RJ.

Transthoracic delivery of large devices into the left ventricle through the right ventricle and interventricular septum: preclinical feasibility.

J Cardiovasc Magn Reson. 2013 Jan 18;15(1):10. PubMed PMID: 23331459.

Impact Factor of 4.435 (CARDIAC & CARDIOVASCULAR SYSTEMS 25/124, Q1 or RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 11/120, Q1)

Times Cited: 5

B1-43 Badr S, Ben-Dor I, Dvir D, **Barbash IM**, Kitabata H, Minha S, Pendyala LK, Loh JP, Torguson R, Pichard AD, Waksman R.

The state of the excimer laser for coronary intervention in the drug-eluting stent era.

Cardiovasc Revasc Med. 2013 Mar-Apr;14(2):93-8. PubMed PMID: 23332778.

(No Impact Factor)

Times Cited: 1

B1-44 **Barbash IM**, Ben-Dor I, Dvir D, Akbari C, Okubagzi P, O'Donnell S, Ricotta J, Beavers F, Momin T, Satler LF, Pichard AD, Waksman R.

Graft-free surgical retroperitoneal vascular access as bail-out technique for failed percutaneous approach to transcatheter aortic valve replacement.

Cardiovasc Revasc Med. 2013 Jan-Feb;14(1):23-6. PubMed PMID: 23337381.

(No Impact Factor)

Times Cited: 1

B1-45 Kitabata H, Loh JP, Sardi GL, Badr S, Dvir D, **Barbash IM**, Pendyala LK, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.

Comparison of long-term outcomes between everolimus-eluting and sirolimus-eluting stents in small vessels.

Am J Cardiol. 2013 Apr 1;111(7):973-8. PubMed PMID: 23337837.

Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)

Times Cited: 0

B1-46 Pendyala LK, Torguson R, Loh JP, Kitabata H, Minha S, Badr S, Dvir D, **Barbash IM**, Satler LF, Pichard AD, Waksman R.

Comparison of adverse outcomes after contemporary percutaneous coronary intervention in women versus men with acute coronary syndrome.

Am J Cardiol. 2013 Apr 15;111(8):1092-8. PubMed PMID: 23352262.

Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)

Times Cited: 1

- B1-47** **Barbash IM**, Dvir D, Ben-Dor I, Badr S, Okubagzi P, Torguson R, Corso PJ, Xue Z, Satler LF, Pichard AD, Waksman R.
Prevalence and effect of myocardial injury after transcatheter aortic valve replacement.
Am J Cardiol. 2013 May 1;111(9):1337-43. PubMed PMID: 23415511.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 1
- B1-48** Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, **Barbash IM**, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.
Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits.
Am J Cardiol. 2013 Jul 1;112(1):61-7. PubMed PMID: 23561590.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 1
- B1-49** Dvir D, **Barbash IM**, Torguson R, Badr S, Sardi GL, Laynez-Carnicero A, Ben-Dor I, Satler LF, Pichard AD, Waksman R.
Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry).
Cardiovasc Revasc Med. 2013 May-Jun;14(3):128-33. PubMed PMID: 23642502.
(No Impact Factor)
Times Cited: 0
- B1-50** Ben-Dor I, Minha S, **Barbash IM**, Aly O, Dvir D, Dekkissa T, Okubagzi P, Torguson R, Lindsay J, Satler LF, Pichard AD, Waksman R.
Correlation of brain natriuretic peptide levels in patients with severe aortic stenosis undergoing operative valve replacement or percutaneous transcatheter intervention with clinical, echocardiographic, and hemodynamic factors and prognosis.
Am J Cardiol. 2013 Aug 15;112(4):574-9. PubMed PMID: 23683951.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 0
- B1-51** Badr S, Kitabata H, Dvir D, Torguson R, **Barbash IM**, Loh JP, Pichard AD, Waksman R.
Optimal revascularization strategies for percutaneous coronary intervention of distal anastomotic lesions after coronary artery bypass surgery.
J Interv Cardiol. 2013 Aug;26(4):366-71. PubMed PMID: 23795684.
Impact Factor of 1.500 (CARDIAC & CARDIOVASCULAR SYSTEMS 73,124, Q3)
Times Cited: 0
- B1-52** Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, **Barbash IM**, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.
Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.
Am J Cardiol. 2013 Oct 15;112(8):1093-8. PubMed PMID: 23827397.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 0
- B1-53** Pendyala LK, Torguson R, Loh JP, Devaney JM, Chen F, Kitabata H, Minha S, **Barbash IM**, Suddath WO, Satler LF, Pichard AD, Waksman R.
Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention.

- Am Heart J.** 2013 Aug;166(2):266-72. PubMed PMID: 23895809.
Impact Factor of 4.497 (CARDIAC & CARDIOVASCULAR SYSTEMS 23/124, Q1)
Times Cited: 0
- B1-54** **Barbash IM**, Dvir D, Torguson R, Xue Z, Satler LF, Pichard AD, Waksman R.
Prognostic implications of percutaneous coronary interventions performed according to the appropriate use criteria for coronary revascularization.
Cardiovasc Revasc Med. 2013 Nov-Dec;14(6):316-20. PubMed PMID: 23988721.
(No Impact Factor)
Times Cited: 0
- B1-55** Minha S, **Barbash IM**, Dvir D, Loh JP, Badr S, Kitabata H, Pendyala LK, Pichard AD, Torguson R, Waksman R.
Second-generation everolimus-eluting stents compared to first-generation drug-eluting stents in patients treated for multivessel disease.
J Interv Cardiol. 2013 Dec;26(6):561-9. PubMed PMID: 24028183.
Impact Factor of 1.500 (CARDIAC & CARDIOVASCULAR SYSTEMS 73,124, Q3)
Times Cited: 0
- B1-56** **Barbash IM**, Gaglia MA Jr, Torguson R, Minha S, Satler LF, Pichard AD, Waksman R.
Effect of marital status on the outcome of patients undergoing elective or urgent coronary revascularization.
Am Heart J. 2013 Oct;166(4):729-36. PubMed PMID: 24093854.
Impact Factor of 4.497 (CARDIAC & CARDIOVASCULAR SYSTEMS 23/124, Q1)
Times Cited: 1
- B1-57** Dvir D, Waksman R, **Barbash IM**, Kodali SK, Svensson L, Tuzcu EM, Xu K, Minha S, Alu MC, Szeto WY, Thourani V, Makkar R, Kapadia S, Satler LF, Webb JG, Leon MB, Pichard AD.
Outcomes of Patients with Chronic Lung Disease and Severe Aortic Stenosis Treated with Transcatheter- versus Surgical Aortic Valve Replacement or Standard Therapy: Insights from the PARTNER Trial.
J Am Coll Cardiol. 2013 Oct;63(3):269-79. PubMed PMID: 24140659.
Impact Factor of 14.086 (CARDIAC & CARDIOVASCULAR SYSTEMS 3/124, Q1)
Times Cited: 0
- B1-58** Waksman R*, **Barbash IM*** [* Equal contribution], Chan R, Randolph P, Makuria AT, Virmani R.
Beta radiation for renal nerve denervation: initial feasibility and safety.
EuroIntervention. 2013 Oct 22;9(6):738-44. PubMed PMID: 24169134.
Impact Factor of 3.173 (CARDIAC & CARDIOVASCULAR SYSTEMS 40/124, Q2)
Times Cited: 3
- B1-59** Pendyala LK, Minha S, **Barbash IM**, Torguson R, Magalhaes MA, Okubagzi P, Loh JP, Chen F, Satler LF, Pichard AD, Waksman R.
Commercial Versus PARTNER Study Experience With the Transfemoral Edwards SAPIEN Valve for Inoperable Patients With Severe Aortic Stenosis.
Am J Cardiol. 2014 Jan 15;113(2):342-7. PubMed PMID: 24220281.
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 1
- B1-60** Dvir D, Kitabata H, **Barbash IM**, Minha S, Badr S, Loh JP, Chen F, Torguson R, Waksman R.
In vivo evaluation of axial integrity of coronary stents using intravascular ultrasound: Insights on longitudinal stent deformation.

Catheter Cardiovasc Interv. 2014 Sep 1;84(3):397-405. PubMed PMID: 24227477.

Impact Factor of 2.514 (CARDIAC & CARDIOVASCULAR SYSTEMS 55/124, Q2)

Times Cited: 0

- B1-61** Minha S, **Barbash IM**, Dvir D, Ben-Dor I, Loh JP, Pendyala LK, Satler LF, Pichard AD, Torguson R, Waksman R.

Correlates for mortality in patients presented with acute myocardial infarct complicated by cardiogenic shock.

Cardiovasc Revasc Med. 2014 Jan;15(1):13-7. PubMed PMID: 24444472.

(No Impact Factor)

Times Cited: 0

- B1-62** Minha S, Magalhaes MA, **Barbash IM**, Ben-Dor I, Dvir D, Okubagzi PG, Chen F, Torguson R, Kent KM, Suddath WO, Satler LF, Pichard AD, Waksman R.

Impact of Previous Coronary Artery Bypass Grafting on Patients Undergoing Transcatheter Aortic Valve Implantation for Aortic Stenosis.

Am J Cardiol. 2014 Apr 1;113(7):1222-7. PubMed PMID: 24513466.

Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)

Times Cited: 0

- B1-63** Dvir D, Générueux P, **Barbash IM**, Kodali S, Ben-Dor I, Williams M, Torguson R, Kirtane AK, Minha S, Badr S, Pendyala LK, Loh JP, Okubagzi PG, Fields JN, Xu K, Chen F, Hahn RT, Satler LF, Smith C, Pichard AD, Leon MB, Waksman R.

Acquired thrombocytopenia after transcatheter aortic valve replacement: clinical correlates and association with outcomes.

Eur Heart J. 2014 Oct;35(38):2663-71. PubMed PMID: 24598983.

Impact Factor of 14.097, (CARDIAC & CARDIOVASCULAR SYSTEMS 2/124, Q1)

Times Cited: 0

- B1-64** **Barbash IM**, Minha S, Ben-Dor I, Dvir D, Magalhaes MA, Torguson R, Okubagzi P, Satler LF, Pichard AD, Waksman R.

Relation of preprocedural assessment of myocardial contractility reserve on outcomes of aortic stenosis patients with impaired left ventricular function undergoing transcatheter aortic valve implantation.

Am J Cardiol. 2014 May;113(9):1536-42. PubMed PMID: 24641965

Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)

Times Cited: 1

- B1-65** **Barbash IM**, Minha S, Torguson R, Ben-Dor I, Badr S, Loh JP, Satler LF, Pichard AD, Waksman R.

Long-Term Safety and Efficacy of the Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

J Invasive Cardiol. 2014 Apr;26(4):154-60. PubMed PMID: 24717271

Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 69/124, Q3)

Times Cited: 0

- B1-66** **Barbash IM**, Minha S, Gallino R, Lager R, Badr S, Loh JP, Kitabata H, Pendyala LK, Torguson R, Satler LF, Pichard AD, Waksman R.

Operator Learning Curve for Transradial Percutaneous Coronary Interventions: Implications for the Initiation of a Transradial Access Program in Contemporary US Practice.

Cardiovasc Revasc Med. 2014 Mar 13. [Epub ahead of print] PubMed PMID: 24746598

(No Impact Factor)

Times Cited: 2

- B1-67** Minha S, **Barbash IM**, Magalhaes MA, Ben-Dor I, Okubagzi PG, Pendyala LK, Satler LF, Pichard AD, Torguson R, Waksman R.
Outcome comparison of African-American and caucasian patients with severe aortic stenosis subjected to transcatheter aortic valve replacement - A single-center experience.
Catheter Cardiovasc Interv. 2014 Apr 30. [Epub ahead of print] PubMed PMID: 24782407
Impact Factor of 2.514 (CARDIAC & CARDIOVASCULAR SYSTEMS 55/124, Q2)
Times Cited: 0
- B1-68** Giordana F, D'Ascenzo F, Nijhoff F, Moretti C, D'Amico M, Biondi Zocca G, Sinning JM, Nickenig G, Van Mieghem NM, Chieffo A, Dumonteil N, Tchetche D, **Barbash IM**, Waksman R, D'Onofrio A, Lefevre T, Pilgrim T, Amabile N, Codner P, Kornowski R, Yong ZY, Baan J, Colombo A, Latib A, Salizzoni S, Omedè P, Conrotto F, La Torre M, Marra S, Rinaldi M, Gaita F.
Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation.
Am J Cardiol. 2014 Nov 1;114(9):1447-55. PubMed PMID: 25217456
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 0
- B1-69** Minha S, Loh JP, Satler LF, Pendyala LK, **Barbash IM**, Magalhaes MA, Suddath WO, Pichard AD, Torguson R, Waksman R.
Transfer distance effect on reperfusion: timeline of ST-elevation patients transferred for primary percutaneous coronary intervention.
Cardiovasc Revasc Med. 2014 Nov-Dec;15(8):369-74. PubMed PMID: 25223909
(No Impact Factor)
Times Cited: 0
- B1-70** **Barbash IM**, Minha S, Ben-Dor I, Dvir D, Torguson R, Aly M, Bond E, Satler LF, Pichard AD, Waksman R.
Predictors and Clinical Implications of Atrial Fibrillation in Patients with Severe Aortic Stenosis undergoing Transcatheter Aortic Valve Implantation.
Catheter Cardiovasc Interv. 2014 Oct 17. [Epub ahead of print]. PubMed PMID: 25323129
Impact Factor of 2.514 (CARDIAC & CARDIOVASCULAR SYSTEMS 55/124, Q2)
Times Cited: 0
- B1-71** Hamdan A, Wellnhofer E, Konen E, Kelle S, Goitein O, Andrada B, Raanani E, Segev A, **Barbash IM**, Klempfner R, Goldenberg I, Guetta V.
Coronary CT angiography for the detection of coronary artery stenosis in patients referred for transcatheter aortic valve replacement.
J Cardiovasc Comput Tomogr. 2015 January - February;9(1):31-41. PubMed PMID: 25576406
Impact Factor of 4.506 (CARDIAC & CARDIOVASCULAR SYSTEMS 25/125, Q1 or ADIOLGY, NUCLEAR MEDICINE & MEDICAL IMAGING 11/122, Q1)
Times Cited: 0
-
- B1-72** **Barbash IM**, Escarcega RO, Minha S, Ben-Dor I, Torguson R, Goldstein SA, Wang Z, Okubagzi P, Satler LF, Pichard AD, Waksman R.
Prevalence and impact of pulmonary hypertension on patients with aortic stenosis undergoing transcatheter aortic valve replacement.
Am J Cardiol. 2015 May 15;115(10):1435-42. PubMed PMID: 25776456
Impact Factor of 3.209 (CARDIAC & CARDIOVASCULAR SYSTEMS 38/124, Q2)
Times Cited: 0
- B1-73** Fink N, Segev A, **Barbash IM**, Bogdan A, Hamdan A, Mazin I, Maor E, Hay I, Guetta V, Fefer P.

Vascular complications in steroid treated patients undergoing transfemoral aortic valve implantation.

Catheter Cardiovasc Interv. 2015 May 23. doi: 10.1002/ccd.26014. [Epub ahead of print]
PMID: 26010839

B1-74 Koifman E, Segev A, Fefer P, **Barbash IM**, Sabbag A, Medvedovsky D, Spiegelstein D, Hamdan A, Hay I, Raanani E, Goldenberg I, Guetta V.

Comparison of acute kidney injury classifications in patients undergoing transcatheter aortic valve implantation: Predictors and long-term outcomes.

Catheter Cardiovasc Interv. 2015 Aug 13. doi: 10.1002/ccd.26138. [Epub ahead of print]
PMID: 26268940

B1-75 Hamdan A, Guetta V, Klempfner R, Konen E, Raanani E, Glikson M, Goitein O, Segev A, **Barbash IM**, Fefer P, Spiegelstein D, Goldenberg I, Schwammenthal E.

Inverse Relationship Between Membranous Septal Length and the Risk of Atrioventricular Block in Patients Undergoing Transcatheter Aortic Valve Implantation.

JACC Cardiovasc Interv. 2015 Aug 17;8(9):1218-28. doi: 10.1016/j.jcin.2015.05.010.
PMID: 26292585

B1-76 **Barbash IM**, Barbanti M, Webb J, Molina-Martin De Nicolas J, Abramowitz Y, Latib A, Nguyen C, Deuschl F, Segev A, Sideris K, Buccheri S, Simonato M, Rosa FD, Tamburino C, Jilaihawi H, Miyazaki T, Himbert D, Schofer N, Guetta V, Bleiziffer S, Tchetche D, Immè S, Makkar RR, Vahanian A, Treede H, Lange R, Colombo A, Dvir D.

Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation.

Eur Heart J. 2015 Dec 14;36(47):3370-9. PMID: 26314688

B1-77 Berkovitch A, Segev A, **Barbash IM**, Grossman Y, Maor E, Erez A, Regev E, Fink N, Mazin I, Hamdan A, Goldenberg I, Hay I, Spiegelstein D, Guetta V, Fefer P.

Clinical impact of diabetes mellitus in patients undergoing transcatheter aortic valve replacement. **Cardiovasc Diabetol.** 2015 Oct 1;14(1):131.
PMID: 26427368

B1-78 Bogdan A*, **Barbash IM*** [*** Equal contribution**], Fefer P, Segev A, Bogdan SN, Asher E, Fink N, Hamdan A, Spiegelstein D, Raanani E, Guetta V.

Albumin predicts long term mortality in elderly patients undergoing trans-catheter aortic valve implantation.

EuroIntervention. 2016 Oct 10;12(8):e1057-e1064. PMID: 27159658

B1-79 **Barbash IM**, Finkelstein A, Barsheshet A, Segev A, Halkin A, Assali A, Ben Gal Y, Vaknin Assa H, Fefer P, Sagie A, Guetta V, Kornowski R.

Outcomes of Patients with Estimated Low, Intermediate and High Risk Undergoing Transcatheter Aortic Valve Implantation for Aortic Stenosis.

Am J Cardiol. 2015 Dec 15;116(12):1916-22. PMID: 26602076

B1-80 Halkin A, Steinvil A, Witberg G, Barsheshet A, Barkagan M, Assali A, Segev A, Fefer P, Guetta V, **Barbash IM**, Kornowski R, Finkelstein A.

Mortality prediction following transcatheter aortic valve replacement: A quantitative comparison of risk scores derived from populations treated with either surgical or percutaneous aortic valve replacement. The Israeli TAVR Registry Risk Model Accuracy Assessment (IRRMA) study.

Int J Cardiol. 2016 Apr 25;215:227-231. PubMed PMID: 27128536.

- B1-81** Landes U, Barsheshet A, Finkelstein A, Guetta V, Assali A, Halkin A, Vaknin-Assa H, Segev A, Bentol T, Ben-Shoshan J, **Barbash IM**, Kornowski R.
Temporal trends in transcatheter aortic valve implantation, 2008-2014: patient characteristics, procedural issues, and clinical outcome.
Clin Cardiol. 2017 Feb;40(2):82-88. PMID: 27783882
- B1-82** Fink N, Segev A, Kornowski R, Finkelstein A, Assali A, Rozenbaum Z, Vaknin-Assa H, Halkin A, Fefer P, Ben-Shoshan J, Regev E, Konigstein M, Orvin K, Guetta V, **Barbash IM**.
Balloon dilatation and outcome among patients undergoing trans-femoral aortic valve replacement.
Int J Cardiol. 2017 Mar 1;230:537-541. PMID: 28040286
- B1-83** Finkelstein A, Minha S, Kornowski R, Danenberg H, Banai S, Lotan H, Segev A, **Barbash IM**.
Israel: coronary and structural heart interventions from 2010 to 2015.
EuroIntervention. 2017 May 15;13(2):Z32-Z36. PMID: 28504227
- B1-84** Witberg G, Regev E, Chen S, Assali A, **Barbash IM**, Planer D, Vaknin-Assa H, Guetta V, Vukasinovic V, Orvin K, Danenberg HD, Segev A, Kornowski R.
The Prognostic Effects of Coronary Disease Severity and Completeness of Revascularization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement.
JACC Cardiovasc Interv. 2017 Jul 24;10(14):1428-1435. PMID: 28728656
- B1-85** Grossman Y, **Barbash IM**, Fefer P, Goldenberg I, Berkovitch A, Regev E, Fink N, Ben-Zekry S, Brodov Y, Kogan A, Guetta V, Raanani E, Segev A.
Addition of albumin to Traditional Risk Score Improved Prediction of Mortality in Individuals Undergoing Transcatheter Aortic Valve Replacement.
J Am Geriatr Soc. 2017 Nov;65(11):2413-2417. PMID: 28941287
- B1-86** Graham Cummiskey A, Segev A, Segel M, Buber J, Guetta V, **Barbash IM**, Elian D, Asher E, Vaturi O, Fefer P.
Exercise Hemodynamics for the Diagnosis of Diastolic Dysfunction in Dyspneic Patients with Systemic Sclerosis.
Isr Med Assoc J. 2018 Apr;20(4):245-249. PMID: 29629733
- B1-87** Berkovitch A, Guetta V, **Barbash IM**, Fink N, Regev E, Maor E, Vered Y, Grossman Y, Younis A, Kuperstein R, Feinberg M, Asher E, Segev A, Fefer P.
Favorable Short-Term and Long-Term Outcomes Among Patients With Prior History of Malignancy Undergoing Transcatheter Aortic Valve Implantation.
J Invasive Cardiol. 2018 Mar;30(3):105-109. PMID: 29493511
- B1-88** Fefer P, Bogdan A, Grossman Y, Berkovitch A, Brodov Y, Kuperstein R, Segev A, Guetta V, **Barbash IM**.
Impact of Rapid Ventricular Pacing on Outcome After Transcatheter Aortic Valve Replacement.
J Am Heart Assoc. 2018 Jul 9;7(14). PMID: 29987119

B.1. Articles Accepted

B1-

B.1. Articles Submitted**B1-****B.2. CASE REPORTS****B.2. Case Reports published**

- B2-1** **Barbash IM**, Waksman R, Kent KM.
Utilization of intravascular ultrasound to accurately position stents in true aorto-ostial lesions.
Cardiovasc Revasc Med. 2012 Nov-Dec;13(6):353-6. PubMed PMID: 23084323.
(No Impact Factor)
Times Cited: 1
- B2-2** Erez A, **Barbash IM**, Spiegelstein D, Kogan A, Hamdan A, Shinfeld A, Preisman S, Segev A.
Extrinsic compression of the left main coronary artery by a contained aortic annular rupture
following trans-catheter aortic valve implantation.
Cardiovasc Revasc Med. 2015 Jul-Aug;16(5):313-6. PubMed PMID: 26100974.
(No Impact Factor)
Times Cited:
-
- B2-3** **Barbash IM**, Bogdan A, Fefer P, Spiegelstein D, Raanani E, Beinart R, Guetta V, Segev A.
How should I treat: A balloon expandable transcatheter heart valve that migrated to the left
ventricular outflow tract.
Eurointervention. 2016 Mar;11(12):1442-5. PMID: 26999684
Impact Factor of 3.173 (CARDIAC & CARDIOVASCULAR SYSTEMS 40/124, Q2)

B.2. Case Reports Accepted**B2-****B.3. REVIEW ARTICLES****B.3. Review Articles Published**

- B3-1** Aboulafia-Etzion S, Leor J, **Barbash IM**, Battler A.
Fixing a failing heart: molecular and cellular approaches.
Harefuah. 1999 Feb 15;136(4):284-8. Review. Hebrew. PubMed PMID: 10914220.
(No Impact Factor)
Times Cited: 2
- B3-2** **Barbash IM**, Gottlieb S, Goldbourt U, Behar S, Leor J.
Aspirin and ACE-inhibitors: for wedding or funeral?
J Thromb Thrombolysis. 2001 Apr;11(2):163-9. Review. PubMed PMID: 11406732.
Impact Factor of 1.985 (HEMATOLOGY 44/67, Q3 or PERIPHERAL VASCULAR DISEASE 39/68, Q3)
Times Cited: 1
- B3-3** **Barbash IM**, Goldbourt U, Gottlieb S, Behar S, Leor J.

- Possible interaction between aspirin and ACE inhibitors: update on unresolved controversy.
Congest Heart Fail. 2000 Nov-Dec;6(6):313-318. PubMed PMID: 12189336.
(No Impact Factor)
Times Cited: 1
- B3-4** Leor J, **Barbash IM**.
Cell transplantation and genetic engineering: new approaches to cardiac pathology.
Expert Opin Biol Ther. 2003 Oct;3(7):1023-39. Review. PubMed PMID: 14519068.
Impact Factor of 3.345 (BIOTECHNOLOGY & APPLIED MICROBIOLOGY 38/160, Q1)
Times Cited: 5
- B3-5** **Barbash IM**, Leor J.
Myocardial regeneration by adult stem cells.
Isr Med Assoc J. 2006 Apr;8(4):283-7. Review. PubMed PMID: 16671368.
Impact Factor of 0.978 (MEDICINE, GENERAL & INTERNAL 83/155, Q3)
Times Cited: 3
- B3-6** **Barbash IM**, Waksman R.
Current status, challenges and future directions of drug-eluting balloons.
Future Cardiol. 2011 Nov;7(6):765-74. Review. PubMed PMID: 22050063.
(No Impact Factor)
Times Cited: 6
- B3-7** **Barbash IM**, Waksman R.
Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the Edwards SAPIEN™ transcatheter heart valve.
Circulation. 2012 Jan 24;125(3):550-5. PubMed PMID: 22271848.
Impact Factor of 15.202 (CARDIAC & CARDIOVASCULAR SYSTEMS 1/124, Q1)
Times Cited: 3
- B3-8** Dvir D, **Barbash IM**, Ben-Dor I, Okubagzi P, Satler LF, Waksman R, Pichard AD.
The development of transcatheter aortic valve replacement in the USA.
Arch Cardiovasc Dis. 2012 Mar;105(3):160-4. Epub 2012 Mar 17. Review. PubMed PMID: 22520799.
Impact Factor of 1.662 (CARDIAC & CARDIOVASCULAR SYSTEMS 67/124, Q3)
Times Cited: 1
- B3-9** Loh JP, **Barbash IM**, Waksman R.
Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the CardioMEMS Champion Heart Failure Monitoring System.
J Am Coll Cardiol. 2013 Apr 16;61(15):1571-6. Review. PubMed PMID: 23352783.
Impact Factor of 14.086 (CARDIAC & CARDIOVASCULAR SYSTEMS 3/124, Q1)
Times Cited: 0
- B3-10** **Barbash IM**, Dvir D, Waksman R.
Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN transcatheter heart valve for high-risk aortic stenosis patients.
Am Heart J. 2013 May;165(5):710-5. PubMed PMID: 23622907.
Impact Factor of 4.497 (CARDIAC & CARDIOVASCULAR SYSTEMS 23/124, Q1)
Times Cited: 0
- B3-11** Dvir D, **Barbash IM**, Ben-Dor I, Torguson R, Badr S, Minha S, Pendyala LK, Loh JP, Pichard AD, Waksman R.
Paravalvular regurgitation after transcatheter aortic valve replacement: diagnosis, clinical outcome, preventive and therapeutic strategies.
Cardiovasc Revasc Med. 2013 May-Jun;14(3):174-81. PubMed PMID: 23773501.
(No Impact Factor)
Times Cited: 1

- B3-12** **Barbash IM**, Waksman R.
 Sympathetic renal denervation: hypertension beyond SYMPPLICITY.
Cardiovasc Revasc Med. 2013 Jul-Aug;14(4):229-35. PubMed PMID: 23928314.
 (No Impact Factor)
 Times Cited: 1
- B3-13** Loh JP, **Barbash IM**, Waksman R.
 The current status of drug-coated balloons in percutaneous coronary and peripheral interventions.
EuroIntervention. 2013 Dec 23;9(8):979-88. PubMed PMID: 24384294.
 Impact Factor of 3.173 (CARDIAC & CARDIOVASCULAR SYSTEMS 40/124, Q2)
 Times Cited: 0

C. CHAPTERS IN BOOKS

- C-1** Leor J, **Barbash IM**, Battler A, Kloner RA.
 Treatment of cardiogenic shock: Future perspectives.
 In: Holmes D, Hasdai D, Battler A, Berger P.
Cardiogenic shock: diagnosis and management.
 The Humana Press, Totowa NJ. 2002.
- C-2** **Barbash IM**, Dvir D, Weigold WG, Satler LF, Waksman R, Pichard AD.
 Trans-catheter aortic valve replacement in patients with chronic kidney disease: Pre-procedural assessment and procedural techniques to minimize risk for acute kidney injury.
 In: Min JK, Berman DS, Leipsic J.
Multimodality Imaging for Transcatheter Aortic Valve Replacement.
 Springer Publishing Company, New York, NY. 2014.
- C-3** Baker N, **Barbash IM**, Waksman R.
 NOVOSTE: The Brachytherapy Approach to Renal Denervation.
 In: Heuser R, Schlaich M, Sievert H.
Renal Denervation: A New Approach to Treatment of Resistant Hypertension.
 Springer Publishing Company, New York, NY. 2014.

D.1. INVITED PAPERS IN SCIENTIFIC MEETINGS

INVITED LECTURES IN SCIENTIFIC MEETINGS

- D1-1 **Barbash IM**.
 Cardiogenic Shock: Israel Experience. Intensive Cardiac Care 2nd International meeting, Jerusalem, Israel. June 2000.
- D1-2 **Barbash IM**.
 Options for cell therapy and cardiac repair. European Society of Cardiology Congress, Munich, Germany. August 2004.
- D1-3 **Barbash IM**.
 Cell Therapy – Overview. 4th International Meeting, Intensive Cardiac Care, Tel-Aviv, Israel, September 2005.
- D1-4 **Barbash IM**.
 Cardiac Stem Cells and Their Role in Myocardial Regeneration. The 11th Annual Meeting of The Israeli Society for Research, Prevention and Treatment of Atherosclerosis in Conjunction with The Frontiers in Cardiovascular Science. Eilat, Israel. October 2006.

D1-5	<u>Barbash IM.</u> Cardiac Stem Cells. 5 th International Meeting, Intensive Cardiac Care, Tel-Aviv, Israel. October 2007.
D1-6	<u>Barbash IM.</u> Resident Cardiac Stem Cells and Their Role in Myocardial Regeneration and Repair. Innovations in Cardiovascular Interventions, Tel-Aviv, Israel. December 2007.
D1-7	<u>Barbash IM</u> How to build a successful TAVI research program. CRT 2013 meeting. Washington DC. February 2013.
D1-8	<u>Barbash IM</u> Mitral Innovations for Treating MR: The Israeli Experience. CRT 2015 meeting. Washington DC. February 2015.

D.2. PAPERS PRESENTED AT SCIENTIFIC MEETINGS PUBLISHED AS ABSTRACTS**ABSTRACTS PRESENTED AT INTERNATIONAL MEETINGS**

- D3-1. Barbash IM, Leor J, Ilia R, Battler A. *Cardiac catheterization facilities and outcome after cardiogenic shock: some bad news, some good news.* *Eur Heart J* 1997; 18: 173A.
- D3-2. Barbash IM, Behar S, Battler A, Boyko V, Gottlieb S, Leor J For The Israeli Thrombolytic Survey Group. *On-site catheterization facilities improve the outcome of unselected patients with cardiogenic shock.* *J Am Coll Cardiol* 1998; 31:13A.
- D3-3. Leor J, Aboulafia-Etzion S, Barbash IM, Rovner M, Rosenstein G, Battler A. *Influence of fetal cardiomyocyte transplantation on the progression of heart failure.* *J Mol Cell Cardiol* 1998;30:A23.
- D3-4. Barbash IM, Leor J, Battler A, Boyko V, Gottlieb S, Behar S for the Israeli Thrombolytic Survey Group. *Trends in management and prognosis of unselected myocardial infarction patients with cardiogenic shock: A national study.* *Journal of the Israel Heart Society*, 1998. Supp: 9.
- D3-5. Barbash IM, Behar S, Battler A, Boyko V, Gottlieb S, Leor J for the Israeli Thrombolytic Survey Group. *On-site catheterization facilities improve the outcome of unselected patients with cardiogenic shock.* *Journal of the Israel Heart Society*, 1998. Supp: 17.
- D3-6. Leor J, Aboulafia-Etzion S, Shapiro L, Barbash IM, Battler A, Granot Y, Cohen S. *Bioengineered grafts to repair the infarcted myocardium.* *Eur Heart J* 1999;20:29 (340).
- D3-7. Aboulafia-Etzion S, Leor S, Barbash IM, Manor O, Granot Y, Battler A. *Cardiomyoblast-mediated ex vivo gene transfer into the infarcted myocardium.* *Eur Heart J* 1999;20:374.
- D3-8. Leor J, Aboulafia-Etzion S, Barbash IM, Rovner M, Granot Y, Battler A. *Influence of Fetal Cardiomyocyte Transplantation on the Progression of Heart Failure.* *J Am Coll Cardiol* 1999;894-1.
- D3-9. Leor J, Aboulafia-Etzion S, Shapiro L, Barbash IM, Battler A, Granot Y, Cohen S. *Bioengineered Grafts to repair the infarcted myocardium.* *Circulation* 1999; 100(18): I-91 (467).
- D3-10. Aboulafia-Etzion S, Leor J, Barbash IM, Manor, Granot Y, Battler A. *Cardiomyoblast-mediated ex vivo gene transfer into the infarcted myocardium.* *Journal of the Israel Heart Society*, 1999. Supp: 9.
- D3-11. Kobal S, Leor J, Barbash IM, Gilutz H, Crystal E, Ilia R, Battler A. *Preinfarction angina enhances mechanical reperfusion and outcome in patients with cardiogenic shock.* *Journal of the Israel Heart Society*, 1999. Supp: 6.
- D3-12. Aboulafia-Etzion S, Leor J, Barbash IM, Manor O, Granot Y, Battler A. *Cardiomyoblast-Mediated Ex Vivo Gene Transfer into the Infarcted Myocardium.* *J Am Coll Cardiol* 2000. 35(2A):228 (1185-126).
- D3-13. Barbash IM, Battler A, Behar S, Gottlieb S, Boyko V, Hasdai D, Ilia R, Leor J. *Timing of Cardiogenic Shock is an Independent Predictor of Outcome.* *J Am Coll Cardiol* 2000. 35(2A):390 (1150-94).
- D3-14. Mardor Y, Barbash IM, Feinberg MS, Tessone A, Aboulafia-Etzion S, Orenstein A, Ruiz-Cabello J, Cohen JS, Leor J. *Interventional MRI For Monitoring Changes in Morphology of Rat Heart Following Myocardial Infarction and Assessing Guided Percutaneous Therapy.* 9th scientific

- meeting of the International Society of Magnetic Resonance in Medicine, Glasgow April 2001. p 1909.
- D3-15. Barbash IM, Etzion S, Fienberg ES, Chouraqui P, Baron J, Tessone A, Tzipori D, Leor J. *Bone marrow-derived mesenchymal stem cells can be injected into the systemic circulation and home into the ischemic myocardium*. Eur Heart J 2001.
- D3-16. Barbash IM, Freimark D, Hod H, Boyko V, Hasin Y, Gottlieb S, Behar S, Leor J. *The benefit of aspirin in acute myocardial infarction is greatest when it is given before hospital admission*. Eur Heart J 2001.
- D3-17. Tessone A, Barbash IM, Gottlieb S, Battler A, Hasin Y, Boyko V, Porath A, Behar S, Leor J. *Management and outcome of patients with chronic renal failure presenting with acute myocardial infarction: results from the national registry ACSIS 2000*. Eur Heart J 2001.
- D3-18. Etzion S, Barbash IM, Feinberg MS, Ilia R, Kloner RA, Kedes L, Leor J. *Genetically modified fibroblasts obtained from the infarcted myocardium as donor cells for transplantation*. Eur Heart J 2001.
- D3-19. Gottlieb S, Leor J, Barbash IM, Garty M, Porath A, Battler A, Grossman E, Hasin Y, Behar S. *Early administration of lipid lowering drugs to patients with acute myocardial infarction is associated with significant reduction in mortality*. Eur Heart J 2001.
- D3-20. Gottlieb S, Leor J, Barbash IM, Haim M, Boyko V, Behar S. *Use of lipid-lowering drugs at discharge in patients with acute myocardial infarction: data from the ACS Israel survey, 2000*. Eur Heart J 2001.
- D3-21. Etzion S, Barbash IM, Feinberg MS, Ilia R, Kloner RA, Kedes L, Leor J. *Cellular Cardiomyoplasty of Cardiac Scar Fibroblasts by Adenoviral Delivery of MyoD Ex Vivo: A New Unlimited Source of Cells for Transplantation*. Circulation 2001.
- D3-22. Barbash IM, Freimark D, Gottlieb S, Hod H, Battler A, Hasin Y, Crystal E, Boyko V, Behar S, Leor J. *Survival of Myocardial Infarction Patients Treated With Aspirin is Enhanced by Pre-Hospital Administration*. J Am Coll Cardio 2002.39(5A):1003-36.
- D3-23. Tessone A, Barbash IM, Gottlieb S, Battler A, Hasin Y, Boyko Y, Porat A, Behar S, Leor J. *Underuse of Evidence-Based Medicine and Outcome of Acute Myocardial Infarction Patients with Renal Failure*. J Am Coll Cardio 2002. 39(5A):1145-45 (abstract).
- D3-24. Leor J, Guetta E, Galski H, Barbash IM, Miller L, Weiser I, Feinberg MS, Nagler A. *Infusion of human umbilical cord blood-derived AC 133+ stem cells to treat myocardial infarction*. Eur Heart J 2003. 24(Suppl. 1):225.
- D3-25. Itzhaki A, Leor J, Mishali D, Sheich Yosef B, Raanani E, Barbash IM. *The hearts of patients with heart disease retain progenitor cells with regenerative capacity*. J Mol Cell Cardiol 2007.42:S94.
- D3-26. Netser S, Leor J, Galski H, Chouraqui B, Baron J, Nagler A, Barbash IM. *Reprogramming human mononuclear cells to express CXCR4 improves homing and engraftment in the infarcted heart*. J Mol Cell Cardiol 2007.42:S97.
- D3-27. Barbash IM, Itzhaki A, Raanani E, Mishali D, Sheich Yosef B, Leor J. *Cardiac Cells with Stem Cell Characteristics Can Be Isolated from Patients with Various Heart Diseases*. Circ Res 2007.101(5): E58 (abstract)
- D3-28. Itzhaki-Alfia A, Leor J, Netser S, Sternik L, Mishaly D, Lavee J, Raanani E, Barbash IM. *The Right Atrium of Patients with Various Heart Diseases Retain Progenitor Cells with Regenerative Capacity*. Circulation 2007. 116(16)Suppl II:133-4.
- D3-29. Itzhaki-Alfia A, Leor J, Netser S, Sternik L, Spiegelstein D, Mishaly D, Lavee J, Raanani E, Barbash IM. *The right atrium is the best source of cardiac progenitor cells in patients with heart disease*. International Society for Stem Cell Research (ISSCR) Meeting, Philadelphia, USA, 2008.
- D3-30. Netser S, Leor J, Chouraqui P, Baron J, Feinberg MS, Nagler A, Barbash IM. *Over expression of CXCR4 on mononuclear cells improves cell homing, retention and survival in the infarcted heart*. Eur Heart J 2008. 29(1):367.
- D3-31. Itzhaki-Alfia A, Leor J, Netser S, Sternik L, Mishaly D, Lavee J, Raanani E, Barbash IM. *The right atrium is the best source of cardiac progenitor cells in patients with heart disease*. Eur Heart J 2008. 29(1):369.

- D3-32. Itzhaki-Alfia A, Leor J, Raanani E, Sternik L, Spiegelstein D, Holbova R, Lavee J, Barbash IM. *Isolation of c-kit positive cardiac progenitor cells from the human heart: Origin of cells and correlation with patient characteristics.* *Heart Fail Suppl* 2009; 8(Suppl. 2):ii670.
- D3-33. Itzhaki-Alfia A, Leor J, Raanani E, Sternik L, Spiegelstein D, Holbova R, Lavee J, Barbash IM. *Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells.* International Society for Stem Cell Research (ISSCR) meeting, Barcelona, Spain 2009.
- D3-34. Itzhaki-Alfia A, Barbash IM, Raanani E, Sternik L, Spiegelstein D, Netser S, Holbova R, Lavee J, Leor J. *Patient Characteristics and Cell Source Determine the Number of Isolated Human Cardiac Progenitor Cells.* *Basic Cardiovascular Sciences 2009 Scientific Sessions. Circ Res* 2009.
- D3-35. Saikus C, Sonmez M, Barbash IM, Wu V, Bell J, Yeung C, Lederman RJ, Kocaturk O. *Post-mortem in-situ vs in vitro and in vivo RF Safety Evaluation of a Two-Channel Intravascular Active Guidewire for Cardiovascular Interventional MRI.* *Proceedings of the 18th Annual Meeting of ISMRM*, Stockholm, Sweden, 2010 (Abstract 1856).
- D3-36. Bell J, Saikus C, Ratnayaka K, Barbash IM, Faranesh A, Slack M, Lederman RJ, Kocaturk O. *An Active Delivery Cable for VSD Closure under MRI-guidance.* *Proceedings of the 18th Annual Meeting of ISMRM*, Stockholm, Sweden, 2010 (Abstract 4154).
- D3-37. Saikus C, Ratnayaka K, Barbash IM, Kocaturk O, Faranesh A, Lederman RJ. *Direct MRI-Guided Needle Access to the Heart and Blood Vessels.* *Proceedings of the 18th Annual Meeting of ISMRM*, Stockholm, Sweden, 2010 (Abstract 290).
- D3-38. Laynez A, Torguson R, Hauville C, Sardi G, Ben Dor I, Maluenda G, Gaglia MA, Gonzalez MA, Barbash IM, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R. Safety and Efficacy for the Use of Prasugrel in Patients Undergoing Percutaneous Coronary Intervention and Anticoagulated with Bivalirudin. *J Am Coll Cardiol.* 2011;58(20) (Supp. B):B45.
- D3-39. Sardi GL, Gaglia MA, Laynez-Carnicero A, Maluenda G, Barbash IM, Ben Dor I, Gonzalez MA, Torguson R, Hauville C, Pakala R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R. On-Treatment Platelet Reactivity Before Coronary Artery Bypass Surgery is Associated with In-Hospital Major Bleeding. Results of a Prospective Evaluation. *J Am Coll Cardiol.* 2011;58(20) (Supp. B):B49
- D3-40. Barbash IM, Torgusson R, Ben Dor I, Maluenda G, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R. Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First Generation Drug-Eluting Stents in Contemporary Clinical Practice. *J Am Coll Cardiol.* 2011;58(20) (Supp. B):B60-61
- D3-41. Gaglia MA, Torguson R, Xue Z, Ben Dor I, Maluenda G, Sardi G, Barbash IM, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R. Married Patients Suffer Less Death and Myocardial Infarction After Percutaneous Coronary Intervention. *J Am Coll Cardiol.* 2011;58(20) (Supp. B):B108
- D3-42. Sardi GL, Torguson R, Maluenda G, Laynez-Carnicero A, Gaglia MA, Barbash IM, Gonzalez M, Hauville C, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R. No Difference in Periprocedural Myocardial Infarction Between Direct Stenting and Balloon Pre-Dilatation During Elective Percutaneous Coronary Intervention. *J Am Coll Cardiol.* 2011;58(20) (Supp. B):B103
- D3-43. Ben Dor I, Barbash IM, Maluenda G, Hauville C, Laynez A, Gaglia MA, Sardi G, Torguson R, Xue Z, Lindsay J, Kent KM, Satler LF, Pichard AD, Waksman R. Femoral Artery Complications Associated with Mynx vs. Suture-Mediated Closure Device vs. Collagen-Based Closure Device. *J Am Coll Cardiol.* 2011;58(20) (Supp. B):B145-6
- D3-44. Barbash IM, Ben Dor I, Maluenda G, Corso PJ, Goldstein SA, Wang Z, Torguson R, Satler LF, Pichard AD, Waksman R. Predictors and Clinical Outcome of Patients with Acute Kidney Injury Following Trans-Cutaneous Aortic Valve Replacement. *J Am Coll Cardiol.* 2011;58(20) (Supp. B):B196
- D3-45. Hauville C, Ben Dor I, Laynez-Carnicero A, Sardi G, Maluenda G, Barbash IM, Gonzalez MA, Gaglia MA, Torguson R, Suddath WO, Satler LF, Kent KM, Lindsay JM, Pichard AD, Waksman R. Does Left Atrial Diameter in Patients with Severe Aortic Stenosis Have a Clinical Impact on Outcome? *J Am Coll Cardiol.* 2011;58(20) (Supp. B):B197

- D3-46. Laynez Carnicero A, Ben-Dor I, Hauville C, Maluenda G, Barbash IM, Kitabata H, Dvir D, Badr S, Torguson R, Xue Z, Suddath W, Satler L, Pichard A, Waksman R. Incidence of Conduction Disturbances and Need for Permanent Pacemaker After Transcatheter Implantation of an Edwards SAPIEN Aortic Valve Prosthesis. *J Am Coll Cardio* 2012. 59(13):A487 (abstract 151-276).
- D3-47. Dvir D, Barbash IM, Torguson R, Xue Z, Badr S, Sardi G, Laynez Carnicero A, Ben-Dor I, Satler L, Pichard A, Waksman R. Clinical Outcomes After Treating Acute Coronary Syndrome Patients With a Drug-Eluting Stent: Results From REWARDS-EMI (Endeavor for Myocardial Infarction Registry). *J Am Coll Cardio* 2012. 59(13):A91 (abstract 1159-596).
- D3-48. Barbash IM, Dvir D, Ben-Dor I, Torguson R, Xue Z, Satler L, Kent K, Pichard A, Waksman R. Performance of Percutaneous Coronary Intervention According to the Appropriateness Use Criteria Does Not Improve Patient Outcome. *J Am Coll Cardio* 2012. 59(13):A454 (abstract 1258-378).
- D3-49. Barbash IM, Dvir D, Torguson R, Xue Z, Badr S, Suddath W, Satler L, Kent K, Pichard A, Waksman R. Publication of Percutaneous Coronary Intervention Appropriateness Use Criteria Does Not Have an Impact on Patient Outcome: A Single-Center Experience. *J Am Coll Cardio* 2012. 59(13):A456 (abstract 1260-468).
- D3-50. Barbash IM, Ben-Dor I, Dvir D, Corso P, Boyce S, Goldstein S, Wang Z, Torguson R, Satler L, Pichard A, Waksman R. Prevalence and Impact of Myocardial Injury Following Transfemoral and Transapical Transcatheter Aortic Valve Replacement. *J Am Coll Cardio* 2012. 59(13A):A2 (Abstract 2500-15).
- D3-51. Barbash IM, Ben-Dor I, Dvir D, Corso P, Boyce S, Goldstein S, Wang Z, Torguson R, Laynez Carnicero A, Satler L, Pichard A, Waksman R. Regional Apical Motion Abnormality Early After Transapical Aortic Valve Replacement: Prevalence and Outcome. *J Am Coll Cardio* 2012. 59(13):A80 (abstract 2507-15).
- D3-52. Dvir D, Barbash IM, Torguson R, Zhenyi Xue, Sardi G, Badr S, Laynez Carnicero A, Ben Dor I, Satler L, Pichard A, Waksman A. First- Versus Second- Generation Drug-Eluting Stents in the Treatment of ST-Segment Elevation Acute Myocardial Infarction. *J Am Coll Cardio* 2012. 59(13A):A10 (abstract 2520-156).
- D3-53. Barbash IM, Ben Dor I, Dvir D, Torguson R, Xue Z, Satler L, Suddath W, Kent K, Pichard A, Waksman R. Clinical Correlates for Failure of Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction. *J Am Coll Cardio* 2012. 59(13A):A13 (abstract 2520-152).
- D3-54. Sardi G, Laynez Carnicero A, Torguson R, Badr S, Barbash IM, Dvir D, Xue W, Suddath W, Kent K, Pichard A, Satler L, Waksman R. Novel Telecommunications Software for Two-Way Interaction During STEMI Management Improves Door-to-Balloon Times. *J Am Coll Cardio* 2012. 59(13A):A18 (abstract 2523-287).
- D3-55. Dvir D, Ben Dor I, Barbash IM, Torguson R, Badr S, Sardi G, Laynez Carnicero A, Satler L, Pichard A, Waksman R. Performing Transfemoral Aortic Valve Replacement Under Local Anesthesia and Conscious Sedation Versus General Anesthesia and Tracheal Intubation in High-Risk Patients With Severe Aortic Stenosis. *J Am Coll Cardio* 2012. 59(13):A55 (abstract 2533-232).
- D3-56. Dvir D, Ben Dor I, Barbash IM, Torguson R, Badr S, Sardi G, Laynez Carnicero A, Satler L, Pichard A, Waksman R. Severe Decline in Platelet Count in Patients Treated by Percutaneous Aortic Valve Replacement is Associated with a High In-Hospital Death Rate. *J Am Coll Cardio* 2012. 59(13):A56 (abstract 2533-296).
- D3-57. Ben Dor I, Dvir D, Barbash IM, Okubagzi P, Torguson R, Xue Z, Lindsay J, Satler L, Pichard A, Waksman R. Balloon Aortic Valvuloplasty for Severe Aortic Stenosis as a Bridge to Transcatheter/Surgical Aortic Valve Replacement. *J Am Coll Cardio* 2012. 59(13A):1145-45 (abstract).
- D3-58. Waksman R, Barbash IM; Chan R, Randolph-Jackson P, Baffour R, Seabron R, Hellinga D, Makuria AT, Virmani R. Beta Radiation for Renal Nerve Denervation: Initial Feasibility and Safety. *Circulation*. 2012;126:A12942
- D3-59. Dvir D, Kitabata H, Barbash IM, Loh J, Torguson R, Badr S, Sattler LF, Pichard AD, Waksman R. Axial Integrity of Coronary Stents: Evaluation Using Intravascular Ultrasound. *Circulation*. 2012;126:A18645.

- D3-60. Badr S, Ben-Dor I, Barbash IM, Minha S, Kitabata H, Loh J, Pendyala L, Torguson R, Chen F, Suddath W, Satler LF, Pichard A, Waksman R. The State Of The Excimer Laser For Coronary Intervention In The Drug-eluting Stent Era. *JACC Cardiovasc Interv.* 2013;6(2_S):S1-S1.
- D3-61. Loh JP, Pendyala LK, Kitabata H, Barbash IM, Dvir D, Badr SM, Minha S, Torguson R, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Why Patients Presenting with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention and Treated with Prasugrel are Switching Back to Clopidogrel. *JACC Cardiovasc Interv.* 2013;6(2_S):S2-S2.
- D3-62. Badr S, Kitabata H, Barbash IM, Minha S, Pendyala L, Loh JP, Torguson R, Chen F, Suddath WO, Satler LF, Pichard AD, Waksman R, Bernardo N. Safety and Efficacy of Ultrasound-guided Thrombin Injections at the 'Neck' of Pseudoaneurysms. *JACC Cardiovasc Interv.* 2013;6(2_S):S2-S3.
- D3-63. Minha S, Barbash IM, Dvir D, Ben-Dor I, Loh JP, Badr SM, Kitabata H, Pendyala LK, Satler LF, Pichard AD, Kent KM, Suddath WO, Torguson R, Waksman R. What Are The Correlates For Mortality In Patients Presented With Acute Myocardial Infarct Complicated By Cardiogenic Shock? *JACC Cardiovasc Interv.* 2013;6(2_S):S9-S10.
- D3-64. Badr S, Barbash IM, Minha S, Kitabata H, Loh JP, Pendyala L, Torguson R, Chen F, Suddath WO, Satler LF, Pichard AD, Waksman R. Rotational Atherectomy Prior To And During The Drug-eluting Stent Era: Procedural Outcomes And Clinical Follow-up Results. *JACC Cardiovasc Interv.* 2013;6(2_S):S12-S12.
- D3-65. Loh JP, Kitabata H, Pendyala LK, Barbash IM, Dvir D, Minha S, Badr S, Torguson R, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Is It Safe to Perform Staged Percutaneous Coronary Intervention On Non-Culprit Vessels During the Index Hospitalization in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease? *JACC Cardiovasc Interv.* 2013;6(2_S):S18-S19.
- D3-66. Badr S, Kitabata H, Barbash IM, Minha S, Loh JP, Pendyala L, Torguson R, Chen F, Suddath WO, Satler LF, Pichard AD, Waksman R. Percutaneous Coronary Intervention In Illicit Drug Abusers. *JACC Cardiovasc Interv.* 2013;6(2_S):S24-S24.
- D3-67. Pendyala LK, Loh JP, Kitabata H, Minha S, Torguson R, Barbash IM, Badr S, Dvir D, Satler LF, Pichard AP, Waksman R. Gender Disparity in Young Patients Presenting with Symptomatic Premature Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. *J Am Coll Cardiol Intv.* 2013;6(2_S):S26-S26.
- D3-68. Loh JP, Pendyala LK, Kitabata H, Badr S, Minha S, Dvir D, Barbash IM, Torguson R, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Do Second-Generation Drug-Eluting Stents Outperform First-Generation Drug-Eluting Stents When Used in "Full Metal Jacket" Percutaneous Coronary Intervention Procedures? *JACC Cardiovasc Interv.* 2013;6(2_S):S40-S41.
- D3-69. Barbash IM, Dvir D, Minha S, Ben Dor I, Badr S, Loh JP, Pendyala L, Kitabata H, Torguson R, Okubagzi P, Suddath WO, Satler LF, Kent K, Pichard AD, Waksman R. Clinical Outcome In Patients With Low Left Ventricular Function Undergoing Transcatheter Aortic Valve Replacement. *JACC Cardiovasc Interv.* 2013;6(2_S):S45-S45.
- D3-70. Pendyala LK, Barbash IM, Minha S, Loh JP, Kitabata H, Badr S, Dvir D, Torguson R, Satler LF, Pichard AD, Waksman R. Initial US Experience with Commercial Transfemoral Sapien Transcatheter Heart valve compared to PARTNER Cohort B. *JACC Cardiovasc Interv.* 2013;6(2_S):S45-S46.
- D3-71. Bogdan A, Guetta V, Barbash IM, Hay I, Hamdan A, Feinberg M, Spiegelstein D, Raanani E, Mandelbaum T, Bogdan S, Asher E, Segev A, Fefer P. Intraprocedural heart rate variation predicts late mortality following TAVI. Eurointervention. 2014. Euro14A-POS266
- D3-72. Bogdan A, Segev A, Fefer P, Hay I, Hamdan A, Feinberg M, Spiegelstein D, Raanani E, Dach R, Bogdan S, Asher E, Guetta V, Barbash IM. The periprocedural serum albumin predicts late mortality in TAVI patients. Eurointervention. 2014. Euro14A-POS263
- D3-73. Berkovitch A, Grossman Y, Maor E, Erez A, Regev E, Fink N, Mazin I, Goldenberg I, Barbash IM, Fefer P. Clinical impact of diabetes mellitus in patients undergoing transcatheter aortic valve implantation. The 62nd Annual Conference of the Israeli Heart Society, 2015.

- D3-74. Barbash IM, Finkelstein A, Barshechet A, Segev A, Halkin A, Assali A, Ben Gal Y, Vaknin Assa H, Fefer P, Sagie A, Guetta V, Kornowski R. Improved Outcomes Following TAVI for Aortic Stenosis in Low and Intermediate Risk vs. High Risk Patients: Results from a Multi-Center Israeli TAVI Registry. The 62nd Annual Conference of the Israeli Heart Society, 2015.
- D3-75. Goitein O, Hamdan A, Guetta V, Konen E, Fefer P, Asher E, Hay I, Segev A, Barbash IM. Cardiac MRI -a tool for myocardial characterization of patients with severe aortic stenosis and impaired left ventricular function. The 62nd Annual Conference of the Israeli Heart Society, 2015.
- D3-76. Maor E, Khalaily N, Segal M, Segev A, Fefer P, Asher E, Guetta V, Barbash IM. Mean pulmonary arterial pressure of 20-25 mmHg during right heart catheterization is not associated with increased risk of long term mortality. The 62nd Annual Conference of the Israeli Heart Society, 2015.
- D3-77. Mazin I, Nof E, Guetta V, Segev A, Barbash IM, Eldar M, Glikson M, Beinart R. Long Term Pacemaker Dependency Following Permanent Pacemaker Implantation in Transcatheter Aortic Valve Implantation patients. The 62nd Annual Conference of the Israeli Heart Society, 2015.
- D3-78. Mazin I, Nof E, Guetta V, Segev A, Barbash IM, Eldar M, Glikson M, Beinart R. Long Term Pacemaker Dependency Following Permanent Pacemaker Implantation in Transcatheter Aortic Valve Implantation patients. Heart Rhythm 36th Annual Scientific Sessions, 2015.
- D3-79. Mazin I, Nof E, Guetta V, Segev A, Barbash IM, Eldar M, Glikson M, Beinart R. Long Term Gender Differences in Permanent Pacemaker Recipients Post Percutaneous Aortic Valve Replacement. The 62nd Annual Conference of the Israeli Heart Society, 2015.
- D3-80. Fink N, Fefer P, Barbash IM, Segev A, Regev E, Mazin I, Erez A, Berkovitch A, Grossman Y, Maor E, Hamdan A, Ben-Zekry S, Goldenberg I, Hay I, Spiegelstien D, Guetta V. Septal Hypertrophy is Associated with Decreased Incidence of Para-Valvular Leak Following Trans-femoral Aortic Valve Implantation. The 62nd Annual Conference of the Israeli Heart Society, 2015.
-
- D3-81. Waksman R, Barbash IM, Chan R, Torguson R, Hellings D, Baffour R, Seabron R, Kelodgie F, Virmani R. Renal sympathetic denervation with brachytherapy using beta-radiation catheter. Results from a feasibility and safety preclinical study. European Society of Cardiology Congress 2015. P4415.
- D3-82. Barbash IM, Finkelstein A, Guetta V, Barshechet A, Halkin A, Assali A, Ben Gal Y, Vaknin Assa H, Segev A, Kornowski R. Improved outcomes following TAVI for aortic stenosis in low and intermediate risk vs. high risk patients: results from a multi-center Israeli TAVI registry. European Society of Cardiology Congress 2015. P6016.
- D3-83. Codner P., Levi A., Gargiulo G., Praz F., Hayashida K., Masalha A., Watanabe Y., Mylotte D., Debry N., Barbanti M., Lefevre T., Modine T., Bosmans J., Windecker S., Barbash IM, Sining J., Nickenig G., Barshechet A., Kornowski R. Impact of renal dysfunction on transcatheter aortic valve replacement outcome in a large multicentre cohort. EuroPCR 2016.
- D3-84. Asher E., Beigel R., Barbash IM, Guetta V., Segev A., Fever P., Elian D., Mazin I., Matetzky S. The "burden" of TAVI patients admitted to the intensive coronary care unit. For the platelets and thrombosis in Sheba group (PLATIS-TAVI). EuroPCR 2016.
- D3-85. Landes U, Barshechet A, Assali A, Vaknin-Assa H, Barbash IM, Guetta V, Segev A, Finkelstein A, Halkin A, Ben-Shoshan J, Kornowski. Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome. The 63rd Annual Conference of the Israeli Heart Society, 2016.
- D3-86. Fink N, Segev A, Finkelstein A, Kornowski R, Barbash IM, Halkin A, Assali A, Rosenbaum Z, Steiniv A, Vaknin-Assa H, Ben Shoshan J, Fefer P, Guetta V. Balloon Post-dilatation and Outcome among Patients Undergoing Trans Aortic Valve Implantation. The 63rd Annual Conference of the Israeli Heart Society, 2016.
- D3-87. Levi A, Codner P, Gargiulo G, Praz F, Hayashida K, Masalha A, Watanabe Y, Mylotte D, Debry N, Barbanti M, Lefevre T, Modine T, Bosmans J, Windecker S, Barbash IM, Sining JM, Barshechet A, Kornowski R. Impact of Renal Dysfunction on Transcatheter Aortic Valve Replacement Outcome in a Large Multicenter Cohort. The 63rd Annual Conference of the Israeli Heart Society, 2016.

- D3-88. Witberg G, Barbash IM, Finkelstein A, Assali A, Segev A, Halkin A, Fefer P, Ben-Shoshan J, Konigstein M, Guetta V, Kornowski R, Barsheshet A. Aortic Valve Gradient and Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. The 63nd Annual Conference of the Israeli Heart Society, 2016.
- D3-89. Shalabi A, Barbash IM, Orlov B, Lipey A, Segev A, Fefer P, Feinberg M, Kogan A, Maor E, Guetta V, Raanani E. Trans-catheter Valve Implantation (TAVI) Versus Sutureless Aortic Valve Replacement in Elderly Patients. The 63rd Annual Conference of the Israeli Heart Society, 2016.
- D3-90. Hamdan A, Shaviv E, Guetta V, Barbash IM, Goitein O, Konen E, Segev A, Fefer P, Assali A, Kornowski R, Schwammthal E. Left Ventricular Mass to Coronary Blood Volume Ratio in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic valve Implantation. The 63nd Annual Conference of the Israeli Heart Society, 2016.
- D3-91. Zeniou V, Chen S, Gilon D, Segev A, Barbash IM, Finkelstein A, Beeri R, Planer D, Shuvy M, Lotan C, Danenberg HD. Ventricular Septal Defect as a Complication of TAVI: Mechanism and Incidence. The 63rd Annual Conference of the Israeli Heart Society, 2016.
- D3-92. Regev R, Guetta V, Kornowski R, Finkelstein A, Orvin K, Halkin A, Landes U, Steinvil A, Levi A, Ben Shoshan J, Barbash IM, Fefer P, Segev A. Transcatheter Aortic Valve Replacement in Patients under the Age of 70. The 63rd Annual Conference of the Israeli Heart Society, 2016.
- D3-93. Goitein O, Komisar O, Barbash IM, Guetta V, Segev A, Fefer P, Asher E, Ben Zikri S, Berkovitz A, Hamdan A, Di Segni E, Orlov B, Konen E, Brodov Y. High Incidence of Renal Artery Stenosis in Post TAVI Acute Kidney Injury. The 63rd Annual Conference of the Israeli Heart Society, 2016.
- D3-94. Witberg G, Barbash IM, Finkelstein A, Assali1 A, Segev A, Halkin A, Fefer A, Ben-Shoshan J, Konigstein M, Guetta V, Kornowski R, Barsheshet A. Aortic valve gradient and mortality in patients undergoing transcatheter aortic valve implantation for severe aortic stenosis. European Society of Cardiology Congress 2016. P838.
- D3-95. Landes U, Barsheshet A, Finkelstein A, Guetta V, Assali A, Halkin A, Vaknin-Assa H, Segev A, Bental T, Ben-Shoshan J, Barbash IM, Kornowski R. Temporal trends in transcatheter aortic valve implantation in Israel 2008-2014: patient characteristics, procedural issues and outcome. European Society of Cardiology Congress 2016. P6464.
- D3-96. Landes U, Segev A, Barbash IM, Almagor Y, Danenberg H, Jaffer R, Sharony R, Orvin K, Levi A, Aassali A, Vaknin-Assa H, Khader N, Hamdan A, Shapira Y, Raanani E, Sagie A, Guetta V, Kornowski R. Transcatheter Valve-in-Valve implantation (ViV) is a less invasive approach to treat patients with bioprosthetic valve deterioration at high risk for redo-surgery. This is the largest registry reporting on ViV experience in Israel. EuroPCR 2017. Euro17A-OP0066.
- D3-97. Sharony R, Nahum E, Assali A, Guetta V, Vaknin Assa H, Barbash IM, Shapira Y, Sagie A, Kuznitz I, Aravot D, Segev A, Kornowski R, Raanani E. Treatment of Mitral Bio-Prosthetic Valve Deterioration Using Trans Apical Valve in Valve Technique: Intermediate-term Outcomes. The 64nd Annual Conference of the Israeli Heart Society, 2017.
- D3-98. Brodov Y, Konen E, Samooha D, Barbash IM, Di Segni M, Guetta V, Segev A, Regev E, Chernomordik F, Glikson M, Goitein O. Impact of of Mitral Annulus Calcifications on Risk of Conduction Disturbances after Transcatheter Aortic Valve Implantation. The 64nd Annual Conference of the Israeli Heart Society, 2017.

G. OTHER PUBLICATIONS (Encyclopedias; Reports; Letter to Editors)

- G-1** Hauville C, Barbash IM, Waksman R.
Same-day discharge after percutaneous coronary intervention. **Letter to the editor.**
JAMA. 2012 Jan 18;307(3):251-2; author reply 252. PubMed PMID: 22253385.
Impact Factor of 29.978 (MEDICINE, GENERAL & INTERNAL 3/155, Q1)

	Times Cited: 0
G-2	Waksman R, <u>Barbash IM.</u> The appropriate use of risk scores. Editorial. JACC Cardiovasc Interv. 2012 Nov;5(11):1106-7. PubMed PMID: 23174633. Impact Factor of 6.552 (CARDIAC & CARDIOVASCULAR SYSTEMS 8/124, Q1)
	Times Cited: 0
G-3	<u>Barbash IM,</u> Waksman R. Reply to Letter to the Editor regarding "Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement". Letter to the editor. Am Heart J. 2013 Feb;165(2):e11. PubMed PMID: 23351829. Impact Factor of 4.497 (CARDIAC & CARDIOVASCULAR SYSTEMS 23/124, Q1)
	Times Cited: 0
G-4	Waksman R, <u>Barbash IM.</u> Radial access as a default for PCI: too early to call. Editorial. Lancet. 2013 Sep 7;382(9895):841-2. PubMed PMID: 23594386. Impact Factor of 39.060 (MEDICINE, GENERAL & INTERNAL 2/155, Q1)
	Times Cited: 0
G-5	<u>Barbash IM,</u> Waksman R, Richard AD. Prevention of right ventricular perforation due to temporary pacemaker lead during transcatheter aortic valve replacement. Letter to the editor. JACC Cardiovasc Interv. 2013 Apr;6(4):427. PubMed PMID: 23597613. Impact Factor of 6.552 (CARDIAC & CARDIOVASCULAR SYSTEMS 8/124, Q1)
	Times Cited: 0
G-6	Magalhaes MA, <u>Barbash IM,</u> Waksman R. Letter by Magalhaes et al regarding article, "Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States". Letter to the editor. Circulation. 2013 Nov 12;128(20):e406. PubMed PMID: 24218446. Impact Factor of 15.202 (CARDIAC & CARDIOVASCULAR SYSTEMS 1/124, Q1)
	Times Cited: 0
G-7	<u>Barbash IM,</u> Guetta V. The boy who cried wolf. Editorial.
G-8	<u>Barbash IM,</u> Raanani E. A journey to the "sweet spot". Editorial. J Thorac Cardiovasc Surg. 2017 Jun;153(6):1316-1317. PMID: 28526100
G-9	Minha S, <u>Barbash IM.</u> TAVR and renal function: A love and hate story. Editorial. Cardiovasc Revasc Med.
G-10	Berkovitch A, <u>Barbash IM.</u> The gender paradox in TAVR. Editorial. Ann Transl Med. 2017 Aug;5(16):329. PMID: 28861426
G-11	<u>Barbash IM,</u> Segev A. The Plan Was to Replace the Valve, Not the Kidneys. Editorial. JACC Cardiovasc Interv. 2017 Oct 23;10(20):2076-2077. PMID: 29050624
G-12	Maor E, <u>Barbash IM</u>

Name: Israel M Barbash

Degree: MD

CV Updated: October 21, 2018

Wrist or Groin? Learning From the Wisdom of the Crowd. **Editorial.**
Cardiovasc Revasc Med. 2018 Mar;19(2):142-143. PMID: 29661492